Yan Huang, Lichang Chen, Rui Huang, Chuanwu Zhu, Jia Shang, Yunsong Qian, . . . Qing Xie. (2022). Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores. SAGE Publishing.
Chicago Style (17th ed.) CitationYan Huang, et al. Tenofovir Is Superior to Entecavir in Reducing HCC for Patients with HBV-related Compensated Cirrhosis at High HCC Risk Scores. SAGE Publishing, 2022.
MLA (9th ed.) CitationYan Huang, et al. Tenofovir Is Superior to Entecavir in Reducing HCC for Patients with HBV-related Compensated Cirrhosis at High HCC Risk Scores. SAGE Publishing, 2022.
Warning: These citations may not always be 100% accurate.